Navigation Links
Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
Date:11/2/2011

CARLSBAD, Calif., Nov. 2, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated Phase 1 clinical studies for ISIS-GCGRRx and ISIS-GCCRRx, antisense drugs Isis is developing for the treatment of type 2 diabetes.  Isis will develop both ISIS-GCGRRx and ISIS-GCCRRx to treat a broad population of diabetic patients.  The unique mechanism of action of these new drugs could allow each drug to be used in combination with other therapies for type 2 diabetes.

"Type 2 diabetes is a progressive disease.  More than half of all diabetic patients cannot reach acceptable glucose control with currently available therapies.  Our goal is to develop safe, effective drugs with unique mechanisms of action that can provide significant therapeutic benefit," said B. Lynne Parshall, Chief Operating Officer, Chief Financial Officer and Secretary of Isis. "This year we have made significant progress toward this goal.  Our ISIS-GCGRRx and ISIS-GCCRRx drugs are designed to reduce the activity of two critical hormones that oppose the action of insulin and cause increased glucose levels in diabetic patients.  The initial clinical development for both of these drugs will focus on treating diabetic patients with moderate to severe diabetes who cannot achieve adequate glucose control with existing treatments.  We believe that each drug could address a significant commercial market by providing long-term disease control in such patients."

ISIS-GCGRRx targets the glucagon receptor (GCGR) to reduce the effects of glucagon, a hormone that causes glucose production in the liver.  Reducing GCGR also increases the production of active glucagon-like peptide (GLP-1), a hormone that preserves pancreatic function and enhances insulin secretion. "Glucagon plays a particularly significant role in increasing blood glucose levels
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes
2. Elusys Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial Scale
3. CryoLife Initiates Enrollment in U.S. Clinical Trial for BioFoam®
4. CareFusion Initiates Class I Recall of EnVe Ventilators
5. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
6. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
7. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
8. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
9. Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes
10. Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain
11. Omthera Pharmaceuticals, Inc. Initiates Phase III ESPRIT Trial of Add-on Epanova™ to Statin Therapy in Patients with Hypertriglyceridemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  Serco Inc., ... announced the Company has been awarded a re-compete ... Command (NEMSCOM) and its Deployable Medical Systems.  Serco ... medical personnel to provide world-class healthcare to meet ... environment across the globe. The five year contract ...
(Date:7/28/2014)... , July 28, 2014  Air Products (NYSE: ... of medical oxygen is vital to any healthcare facility. ... that not only improve the efficiency of its oxygen ... will highlight these systems—including systems for emergency oxygen ... loss—from August 4-5 at the 51 st ...
(Date:7/28/2014)... 2014  VigeneTech, Inc, in collaboration with BioLegend, ... Analysis Software, an OEM software solution for analysis ... and offers varieties of bead-based multi-analyte immunoassay products ... of VigeneTech,s data analysis software, FCS data files ... reported LEGENDplex™ software is a ...
Breaking Medicine Technology:Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 3VigeneTech Releases New Powerful Software for Flow Cytometry Data Analysis 2
... /PRNewswire-FirstCall/ -- Kosan,Biosciences Incorporated announced data will be ... its Hsp90,inhibitor, epothilone and nuclear export inhibitor programs, ... for Cancer Research,(AACR), being held in Los Angeles, ... programs are as follows. The,location for all poster ...
... April 10, 2007--In a study appearing in the ... by the,National Institutes of Healths National Institute of ... a,connection between a specific gene and the inflammatory ... of autoimmune,diseases. , Vitiligo is a chronic condition ...
Cached Medicine Technology:Kosan Announces Data Presentations at Upcoming AACR Annual Meeting 2Kosan Announces Data Presentations at Upcoming AACR Annual Meeting 3Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases 2Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases 3
(Date:7/28/2014)... St. Jude Children’s Research Hospital has ... Defense Employer Support Freedom Award from the Employer Support of ... The award is the highest honor given by the U.S. ... serve in the National Guard and Reserve. , “We deeply ... contributions to the St. Jude mission and to our country,” ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 The ... the majority of professionals engaged in the field ... the Transplantation and Immunology Research Network ... and immunology research. As modern organ transplantation continues ... network that could provide more opportunities for physicians, ...
(Date:7/28/2014)... BEER-SHEVA, ISRAEL, July 28, 2014...Mothers who live near ... weights, according to a new study, "Green Spaces ... Occupational and Environmental Medicine . , A ... Ben-Gurion University of the Negev (BGU), evaluated nearly ... cohort in Tel Aviv, Israel to determine the ...
(Date:7/28/2014)... into improving treatment for patients with one of the ... funding boost. , Chronic obstructive pulmonary disease (COPD) is ... breathing difficulties due to long-term damage to the lungs. ... 10 per cent of all hospital admissions in the ... to hospital after they are discharged. , ...
(Date:7/28/2014)... findings made possible by a test developed at University ... (CU School of Pharmacy), AURORA, Colo (July 28, 2014) ... Colorado Antiviral Pharmacology Laboratory at the CU School of ... drug called Truvada (a combination of tenofovir/emtricitabine), which is ... A study presented during the AIDS 2014 Conference and ...
Breaking Medicine News(10 mins):Health News:St. Jude Children’s Research Hospital Receives Secretary of Defense Employer Support Freedom Award 2Health News:St. Jude Children’s Research Hospital Receives Secretary of Defense Employer Support Freedom Award 3Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:HIV research findings made possible by a test developed at CU School of Pharmacy 2
... powerful therapy to prevent recurrence among certain follicular lymphoma patients, ... the University of Pennsylvania School of Medicine. The new findings ... by a specific protein that may be present in up ... receive a vaccine made from their own tumor cells, disease-free ...
... 2010) The next generation of drug therapies ... lymphoma are evolving as researchers continue to better ... presented today at the 52nd Annual Meeting of ... options for the standard treatment of advanced asymptomatic ...
... remove the resulting excess iron remains the best approach ... patients with sickle cell anemia, according to a preliminary ... Children,s Research Hospital. The study compared the efficacy ... iron overload caused by chronic transfusion therapy. The transfusions ...
... by the National Institute of Allergy and Infectious Diseases ... issued comprehensive U.S. guidelines to assist health care professionals ... people with the disease. The Guidelines for ... United States: Report of the NIAID-sponsored Expert Panel, developed ...
... Lesbian, gay and bisexual (LGB) adolescents are about 40 ... by school authorities, police and the courts, according to ... January 2011 issue of the journal Pediatrics , ... of LGB youth nationwide. "We found that ...
... FRIDAY, Dec. 3 (HealthDay News) -- Although winter hasn,t even ... officials said Friday. In fact, Georgia is seeing a ... the state calling it a regional outbreak. The Georgia cases ... the rest of the country once flu season really gets ...
Cached Medicine News:Health News:Personalized vaccine for lymphoma patients extends disease-free survival by nearly 2 years 2Health News:Personalized vaccine for lymphoma patients extends disease-free survival by nearly 2 years 3Health News:New standards of care and novel treatment options for several forms of lymphoma unveiled 2Health News:New standards of care and novel treatment options for several forms of lymphoma unveiled 3Health News:New standards of care and novel treatment options for several forms of lymphoma unveiled 4Health News:New standards of care and novel treatment options for several forms of lymphoma unveiled 5Health News:New standards of care and novel treatment options for several forms of lymphoma unveiled 6Health News:New standards of care and novel treatment options for several forms of lymphoma unveiled 7Health News:New standards of care and novel treatment options for several forms of lymphoma unveiled 8Health News:New standards of care and novel treatment options for several forms of lymphoma unveiled 9Health News:2 studies provide insight into stroke risk and prevention in young sickle cell anemia patients 2Health News:2 studies provide insight into stroke risk and prevention in young sickle cell anemia patients 3Health News:NIH-sponsored panel issues comprehensive US food allergy guidelines 2Health News:NIH-sponsored panel issues comprehensive US food allergy guidelines 3Health News:Lesbian, gay and bisexual teens singled out for punishment 2Health News:Outbreaks Signal Another Flu Season, CDC Says 2Health News:Outbreaks Signal Another Flu Season, CDC Says 3
The FastPack system is a state of the art, lab quality immunoassay system designed for rapid results. The FastPack system delivers lab-quality sensitivity at a fraction of the cost of laboratory....
... When you need quick, accurate, convenient, and ... compact VITROS DT60 II Chemistry System. This ... and back-up laboratory testing requirements. And it ... -- better patient outcomes, reduced overall costs, ...
... In an effort to improve on ... hormones, toxicology, abused drugs, and immunosuppressants ... 1991 which incorporates random access capabilities. ... has undergone several important changes in ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
Medicine Products: